Jay Olson
Stock Analyst at Oppenheimer
(3.64)
# 759
Out of 4,784 analysts
238
Total ratings
40.11%
Success rate
8.68%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Upgrades: Outperform | $6 | $0.77 | +679.12% | 6 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $50 → $42 | $14.24 | +194.94% | 4 | Mar 3, 2025 | |
| PRTA Prothena Corporation | Maintains: Outperform | $58 → $62 | $12.95 | +378.76% | 13 | Feb 7, 2025 | |
| EXEL Exelixis | Downgrades: Perform | $41 → $33 | $36.83 | -10.40% | 6 | Jan 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $60 → $40 | $8.42 | +375.34% | 9 | Jan 13, 2025 | |
| QTTB Q32 Bio | Maintains: Outperform | $80 → $20 | $1.89 | +958.20% | 2 | Dec 11, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $30 | $3.84 | +682.27% | 1 | Dec 6, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $17 → $20 | $3.05 | +555.74% | 2 | Dec 4, 2024 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $33 → $15 | $1.74 | +762.07% | 2 | Nov 18, 2024 | |
| BIIB Biogen | Maintains: Outperform | $270 → $255 | $139.95 | +82.21% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $9 → $8 | $8.77 | -8.78% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $60.66 | +35.18% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $60 | $37.97 | +58.02% | 8 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $337.00 | +3.86% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $3.13 | +219.19% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $26.11 | +428.63% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.97 | +307.12% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 | $9.15 | +424.59% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $305.88 | +24.23% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $113.42 | +93.09% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $1.30 | +826.64% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.73 | +382.57% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.75 | +1,242.28% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $38.00 | +150.00% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $19 | $17.10 | +11.14% | 14 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.05 | +1,119.51% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $31.34 | +139.35% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.44 | +1,950.11% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 | $4.86 | +1,546.09% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $1.67 | +1,401.50% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $8.59 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $50 | $1.07 | +4,572.90% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $5.87 | +257.75% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.29 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $16.75 | +401.64% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.06 | - | 3 | Jul 11, 2017 |
Nektar Therapeutics
Mar 14, 2025
Upgrades: Outperform
Price Target: $6
Current: $0.77
Upside: +679.12%
Denali Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $14.24
Upside: +194.94%
Prothena Corporation
Feb 7, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $12.95
Upside: +378.76%
Exelixis
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $36.83
Upside: -10.40%
Intellia Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $8.42
Upside: +375.34%
Q32 Bio
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $1.89
Upside: +958.20%
Sagimet Biosciences
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $3.84
Upside: +682.27%
Terns Pharmaceuticals
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $3.05
Upside: +555.74%
Inovio Pharmaceuticals
Nov 18, 2024
Maintains: Outperform
Price Target: $33 → $15
Current: $1.74
Upside: +762.07%
Biogen
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $139.95
Upside: +82.21%
Oct 30, 2024
Maintains: Perform
Price Target: $9 → $8
Current: $8.77
Upside: -8.78%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $60.66
Upside: +35.18%
Oct 28, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $37.97
Upside: +58.02%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $337.00
Upside: +3.86%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $3.13
Upside: +219.19%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $26.11
Upside: +428.63%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.97
Upside: +307.12%
Aug 7, 2024
Maintains: Outperform
Price Target: $48
Current: $9.15
Upside: +424.59%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $305.88
Upside: +24.23%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $113.42
Upside: +93.09%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $1.30
Upside: +826.64%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.73
Upside: +382.57%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.75
Upside: +1,242.28%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $38.00
Upside: +150.00%
May 6, 2024
Maintains: Perform
Price Target: $19
Current: $17.10
Upside: +11.14%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $2.05
Upside: +1,119.51%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $31.34
Upside: +139.35%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.44
Upside: +1,950.11%
Mar 7, 2024
Maintains: Outperform
Price Target: $80
Current: $4.86
Upside: +1,546.09%
Mar 5, 2024
Reiterates: Outperform
Price Target: $25
Current: $1.67
Upside: +1,401.50%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $8.59
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $120 → $50
Current: $1.07
Upside: +4,572.90%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $5.87
Upside: +257.75%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.29
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $16.75
Upside: +401.64%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.06
Upside: -